GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Transplant Rejection overview

Transplant rejection is the immune system’s response to a transplanted organ or tissue, wherein the body recognizes the newly transplanted material as foreign and attempts to eliminate it. This process occurs due to the immune system’s natural defense mechanism against perceived threats. Rejection can be classified as hyperacute, acute, or chronic, with varying timelines and severity. Symptoms may include fever, tenderness, organ dysfunction, or swelling at the transplant site. Prevention involves immunosuppressive medications to suppress the immune response, while treatment may require adjustments in drug regimens or, in severe cases, further interventions. Monitoring and managing rejection are crucial to optimize the success of organ or tissue transplantation.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.